Holger Hinrichsen

7.7k total citations
111 papers, 2.9k citations indexed

About

Holger Hinrichsen is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Holger Hinrichsen has authored 111 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Hepatology, 64 papers in Epidemiology and 11 papers in Rheumatology. Recurrent topics in Holger Hinrichsen's work include Hepatitis C virus research (75 papers), Liver Disease Diagnosis and Treatment (47 papers) and Hepatitis B Virus Studies (46 papers). Holger Hinrichsen is often cited by papers focused on Hepatitis C virus research (75 papers), Liver Disease Diagnosis and Treatment (47 papers) and Hepatitis B Virus Studies (46 papers). Holger Hinrichsen collaborates with scholars based in Germany, United States and Spain. Holger Hinrichsen's co-authors include Thomas Berg, Stefan Zeuzem, Heiner Wedemeyer, Eva Herrmann, Atef Halabi, Michael P. Manns, Tilman Gerlach, Gerhard Nehmiz, Wilhelm Kirch and Markus Reiser and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Holger Hinrichsen

107 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holger Hinrichsen Germany 24 2.3k 2.1k 398 268 199 111 2.9k
Mark Wright United Kingdom 26 1.1k 0.5× 1.2k 0.6× 114 0.3× 185 0.7× 51 0.3× 81 2.1k
Jan van Hattum Netherlands 33 986 0.4× 1.1k 0.5× 167 0.4× 100 0.4× 42 0.2× 69 2.6k
Samuel H. Sigal United States 25 2.8k 1.2× 2.4k 1.2× 311 0.8× 114 0.4× 81 0.4× 80 4.2k
Yoav Lurie Israel 25 1.3k 0.6× 1.5k 0.7× 220 0.6× 189 0.7× 69 0.3× 84 2.4k
Chung‐Feng Huang Taiwan 28 2.3k 1.0× 2.3k 1.1× 171 0.4× 165 0.6× 319 1.6× 204 3.2k
G. Idéo Italy 29 3.6k 1.5× 3.3k 1.6× 270 0.7× 389 1.5× 49 0.2× 99 4.4k
Yueyong Zhu China 26 749 0.3× 1.4k 0.7× 299 0.8× 46 0.2× 121 0.6× 111 2.3k
Nurdan Tözün Türkiye 25 576 0.2× 753 0.4× 98 0.2× 87 0.3× 60 0.3× 106 1.8k
Johannes Wiegand Germany 29 1.8k 0.8× 1.9k 0.9× 271 0.7× 116 0.4× 69 0.3× 132 2.6k
V. Loustaud‐Ratti France 28 1.2k 0.5× 1.2k 0.6× 214 0.5× 633 2.4× 45 0.2× 141 2.9k

Countries citing papers authored by Holger Hinrichsen

Since Specialization
Citations

This map shows the geographic impact of Holger Hinrichsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Hinrichsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Hinrichsen more than expected).

Fields of papers citing papers by Holger Hinrichsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Hinrichsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Hinrichsen. The network helps show where Holger Hinrichsen may publish in the future.

Co-authorship network of co-authors of Holger Hinrichsen

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Hinrichsen. A scholar is included among the top collaborators of Holger Hinrichsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Hinrichsen. Holger Hinrichsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Petersen, Jörg, Wolf Peter Hofmann, Holger Hinrichsen, et al.. (2021). Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany. Journal of Clinical Medicine. 10(5). 1061–1061. 13 indexed citations
2.
Nelson, David R., K. Rajender Reddy, Adrian M. Di Bisceglie, et al.. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials. Hepatology. 60. 5 indexed citations
3.
Heidrich, Benjamin, Steffen B. Wiegand, Peter Buggisch, et al.. (2014). Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. PLoS ONE. 9(10). e108751–e108751. 13 indexed citations
4.
Halabi, Atef, et al.. (2013). Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clinical Pharmacology in Drug Development. 3(4). 290–296. 11 indexed citations
5.
Wiegand, Johannes, Konrad Neumann, Sybille Böhm, et al.. (2011). Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. Clinical Infectious Diseases. 53(11). 1111–1114. 3 indexed citations
6.
Weich, V, Eva Herrmann, Christoph Sarrazin, et al.. (2011). The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. Journal of Gastroenterology. 46(12). 1427–1436. 22 indexed citations
7.
Seeger, Marcus, Rainer Günther, Holger Hinrichsen, et al.. (2010). Chronic Portal Vein Thrombosis: Transcapsular Hepatic Collateral Vessels and Communicating Ectopic Varices. Radiology. 257(2). 568–578. 14 indexed citations
8.
Wedemeyer, Heiner, Elisabeth Schuller, Verena Schlaphoff, et al.. (2009). Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine. 27(37). 5142–5151. 58 indexed citations
9.
Wagner, Michael, Wolf Peter Hofmann, G Teuber, et al.. (2008). Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology. 48(5). 1404–1411. 26 indexed citations
10.
Jahnke, Thomas, et al.. (2007). Transjugulärer intrahepatischer portosystemischer Shunt: Untersuchung des Einflusses der Stentkonfiguration auf die Offenheitsrate. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 179(9). 965–970. 4 indexed citations
11.
Schott, Eckart, Heiko Witt, Holger Hinrichsen, et al.. (2006). Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. Journal of Hepatology. 46(3). 372–380. 39 indexed citations
12.
Wagner, Michael, M Huber, Thomas Berg, et al.. (2005). Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology. 129(2). 522–527. 319 indexed citations
13.
Reiser, Markus, Holger Hinrichsen, Yves Benhamou, et al.. (2005). Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡. Hepatology. 41(4). 832–835. 121 indexed citations
14.
Hinrichsen, Holger, Yves Benhamou, Heiner Wedemeyer, et al.. (2004). Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 127(5). 1347–1355. 233 indexed citations
15.
Hinrichsen, Holger & Ulrich R. Fölsch. (2004). Acute cholecystitis - immediate operation? - contra. DMW - Deutsche Medizinische Wochenschrift. 129(17). 971–971.
16.
Hauschild, Axel, Holger Hinrichsen, & Enno Christophers. (2000). Nebenwirkungen der Interferontherapie und deren Management. Der Hautarzt. 51(10). 793–803. 2 indexed citations
17.
Hinrichsen, Holger, Atef Halabi, & Wilhelm Kirch. (1992). Haemodynamic effects of H2‐receptor antagonists. European Journal of Clinical Investigation. 22(1). 9–18. 11 indexed citations
18.
Hinrichsen, Holger, et al.. (1992). Influence of prolonged neuropsychological testing on immunoregulatory cells and hormonal parameters in patients with systemic lupus erythematosus. Rheumatology International. 12(2). 47–51. 12 indexed citations
19.
Hinrichsen, Holger, Atef Halabi, & Wilhelm Kirch. (1990). Hemodynamic effects of different H2-receptor antagonists. Clinical Pharmacology & Therapeutics. 48(3). 302–308. 27 indexed citations
20.
Hinrichsen, Holger, et al.. (1990). Infective endocarditis at a Hospital of the University of Kiel, 1958–1987. Journal of Molecular Medicine. 68(18). 921–926. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Wright Breakdown of academic impact, for papers by Jan van Hattum Breakdown of academic impact, for papers by Samuel H. Sigal Breakdown of academic impact, for papers by Yoav Lurie Breakdown of academic impact, for papers by Chung‐Feng Huang Breakdown of academic impact, for papers by G. Idéo Breakdown of academic impact, for papers by Yueyong Zhu Breakdown of academic impact, for papers by Nurdan Tözün Breakdown of academic impact, for papers by Johannes Wiegand Breakdown of academic impact, for papers by V. Loustaud‐Ratti
Rankless by CCL
2026